Skip to main content

Table 4 Dengue antibody GMTs and seropositivity status, in YF non-immune participants following CYD-TDV alone (Groups 1 and 2 pooled) or CYD-TDV co-administered with YF vaccine (Group 3)

From: Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults

Time point

Group 1 and 2 pooled, YF− (n = 116)

Group 3, YF− (n = 108)

n

GMT (95% CI)

Seropositive, % (95% CI)

n

GMT (95% CI)

Seropositive, % (95% CI)

Serotype 1

 Baseline

116

5.19 (4.87–5.53)

1.7 (0.2–6.1)

108

5.00 (NC)

0 (0.0–3.4)

 Post-dose 1

116

8.71 (7.04–10.8)

23.3 (15.9–32.0)

108

7.68 (6.46–9.14)

20.4 (13.2–29.2)

Serotype 2

 Baseline

116

5.06 (4.94–5.19)

0.9 (0.0–4.7)

108

5.06 (4.94–5.20)

0.9 (0.0–5.1)

 Post-dose 1

116

18.8 (13.9–25.3)

46.6 (37.2–56.0)

108

10.8 (8.63–13.4)

35.2 (26.2–45.0)

Serotype 3

 Baseline

116

5.21 (4.97–5.47)

2.6 (0.5–7.4)

108

5.28 (4.90–5.69)

2.8 (0.6–7.9)

 Post-dose 1

114

28.5 (20.4–39.7)

57.9 (48.3–67.1)

108

8.88 (7.23–10.9)

25.0 (17.2–34.3)

Serotype 4

 Baseline

116

5.43 (4.99–5.92)

3.4 (0.9–8.6)

108

5.26 (4.90–5.65)

1.9 (0.2–6.5)

 Post-dose 1

114

229 (139–378)

74.6 (65.6–82.3)

107

22.6 (15.9–32.3)

48.6 (38.8–58.5)

  1. YF seronegative participants at baseline are defined as those participants with YF baseline titre < 10 1/dil using PRNT80. Dengue seropositive defined as dengue antibody titres ≥10 (1/dil) against each serotype, and against at least 3 or all 4 serotypes with the parental dengue virus strain
  2. GMT geometric mean titre, n number of participants with available data for endpoint, YF yellow fever